Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short 

Biogenic On Wednesday, the turnover and profit of the fourth quarter achieved the expectations at the top, because the cost reductions showed progress and new products, including the breakthrough Alzheimer treatment Leqembi, growth.

But the guidance of the biotech company for the current year missed the expectations of Wall Street. Biogen issued a full year 2025 adapted profit views from $ 15.25 to $ 16.25 per share, which did not work the $ 16.34 per share that analysts expected, according to LSEG. That reflects a exchange office in the change of 35 cents per share, Biogen said.

Biogen expects the income to fall with a “mid-single figure” percentage in 2025 compared to 2024, while the sale of its multiple sclerosis products will fall. That part of the company has fallen for several quarters, since some of those therapies are confronted with generic competition.

But Biogen expects Leqembi, together with his new rare disease and depression treatments, to compensate for those sliding income this year.

Leqembi generated $ 87 million in income for the fourth quarter, including $ 50 million in the American analysts that the drug would book $ 67 million in turnover, according to estimates of street account.

Leqembi, which shares biogen with the Japanese drug maker Eisai, became the second medicine that proved to delay the progress of Alzheimer's to win approval in the US in 2023. The launch of therapy has been gradual due to bottlenecks related to diagnostic test requirements, the need for regular brain scans and the difficulty to find neurologists, among others.

This is what Biogen reported for the fourth quarter compared to what Wall Street expected, based on a study among analysts by LSEG:

• Profit per share: $ 3.44 adapted versus $ 3.35 per share expected
• Gain: $ 2.46 billion versus $ 2.40 billion expected

Biogen achieved a turnover of $ 2.46 billion for the quarter, which has risen around 3% compared to the period of the year.

The drug maker booked the net income of $ 266.8 million, or $ 1.83 per share, for the quarter. That is comparable to the net income of $ 249.7 million, or $ 1.71 per share, for the same period a year ago.

Adjustment of one -off articles, including certain restructuring costs and costs related to intangible assets, the company reported the profit of $ 3.44 per share.

Biogen first started a cost-saving program in 2023. The company expects to generate $ 1 billion in gross savings by the end of 2025, or $ 800 million net savings.

On Wednesday, Royalty Pharma also announced an agreement to provide $ 250 million in research and development financing to biogen for litifilimab, an important medicine in the pipeline that is studied to treat lupus. Royalty Pharma, a leading financier of the biotech and pharmaceutical industry, is eligible for milestones and certain royalties.

Another new medicine, Skyclarys, booked $ 102 million in sales for the fourth quarter, almost double what it reported in the period of the year.

According to Street account, analysts had expected the turnover of around $ 112 million for the quarter.

Skyclarys came from the acquisition of Biogen of Reata Pharmaceuticals in July 2023. The Food and Drug Administration Greenlit Skyclarys in 2023, making it the first approved treatment for the ataxia of Friedreich, a rare hereditary disaster disease that runs and coordination in children like young As young as 5.

Zurzuvae, the first pill for postpartum depression, generated the turnover of the fourth quarter of $ 22.9 million. Analysts expected that it would post $ 26 million in sales, said Street account estimates.

In the meantime, the turnover of the fourth quarter of Biogen of Multiple Sclerosis treatments fell by 8% to $ 1.07 billion.

Correction: The turnover of the fourth quarter of Biogen of Multiple Sclerosis treatments fell to $ 1.07 billion. An earlier version has gone incorrectly.